Received Jun 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No symptoms reported; Caller reported AE on behalf of a patient who experienced a schedule interruption with GARDASIL 9 vaccination. Caller reported that a patient received their first dose at 19-years old and second dose on 05/28/2025 at 24-years-old. No additional patie; This spontaneous report was received from a pharmacist and refers to a 24-year-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On an unknown date (at the age of 19 years), the patient was vaccinated with the first dose Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), 0.5 mL/dose (route of administration, anatomical location, lot # and expiration date were not reported) as prophylaxis. Then, on 28-MAY-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), 0.5 mL/dose (route of administration, anatomical location, lot # and expiration date were not reported) as prophylaxis (inappropriate schedule of product administration). No symptoms reported (no adverse event). Lot # is being requested and will be submitted if received.